GSK plc - Jul 2, 2021 Form 4 Insider Report for CVRx, Inc. (CVRX)

Role
10%+ Owner
Signature
/s/ Victoria Whyte
Stock symbol
CVRX
Transactions as of
Jul 2, 2021
Transactions value $
$4,950,000
Form type
4
Date filed
7/6/2021, 04:38 PM
Previous filing
Jul 6, 2021
Next filing
Sep 20, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CVRX Common Stock Conversion of derivative security +1.51K +4.73% 33.3K Jul 2, 2021 See Footnote F2, F4
transaction CVRX Common Stock Conversion of derivative security +13K +38.96% 46.3K Jul 2, 2021 See Footnote F2, F4
transaction CVRX Common Stock Conversion of derivative security +14.9K +32.22% 61.2K Jul 2, 2021 See Footnote F2, F4
transaction CVRX Common Stock Conversion of derivative security +8.38K +13.69% 69.6K Jul 2, 2021 See Footnote F2, F4
transaction CVRX Common Stock Conversion of derivative security +27.3K +39.29% 96.9K Jul 2, 2021 See Footnote F2, F4
transaction CVRX Common Stock Conversion of derivative security +636K +655.73% 733K Jul 2, 2021 See Footnote F3, F4
transaction CVRX Common Stock Purchase $4.95M +275K +37.54% $18.00 1.01M Jul 2, 2021 See Footnote F1, F5

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CVRX Series B-2 Preferred Stock Conversion of derivative security $0 -59.5K -100% $0.00* 0 Jul 2, 2021 Common Stock 1.51K See Footnote F2, F4
transaction CVRX Series C-2 Preferred Stock Conversion of derivative security $0 -513K -100% $0.00* 0 Jul 2, 2021 Common Stock 13K See Footnote F2, F4
transaction CVRX Series D-2 Preferred Stock Conversion of derivative security $0 -590K -100% $0.00* 0 Jul 2, 2021 Common Stock 14.9K See Footnote F2, F4
transaction CVRX Series E-2 Preferred Stock Conversion of derivative security $0 -331K -100% $0.00* 0 Jul 2, 2021 Common Stock 8.38K See Footnote F2, F4
transaction CVRX Series F-2 Preferred Stock Conversion of derivative security $0 -1.08M -100% $0.00* 0 Jul 2, 2021 Common Stock 27.3K See Footnote F2, F4
transaction CVRX Series G Preferred Stock Conversion of derivative security $0 -10.1M -100% $0.00* 0 Jul 2, 2021 Common Stock 636K See Footnote F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

GSK plc is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 Glaxo Group Limited acquired 275,000 Common Stock of the Issuer in connection with the Issuer's initial public offering.
F2 The Series B-2 Preferred Stock, Series C-2 Preferred Stock, Series D-2 Preferred Stock, Series E-2 Preferred Stock and Series F-2 Preferred Stock automatically converted into common stock on a 1-for-0.025857287 basis (in each case, subject to the payment of cash in lieu of any fractional shares) without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date.
F3 The Series G Preferred Stock automatically converted into common stock on a 1-for-0.0632143218 basis (subject to the payment of cash in lieu of any fractional shares) without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date.
F4 The shares reported herein are held of record by Action Potential Venture Capital Limited, an indirect, wholly owned subsidiary of GlaxoSmithKline plc (the "Reporting Person").
F5 The shares reported herein are held of record by Glaxo Group Limited, an indirect, wholly-owned subsidiary of the Reporting Person.